Anti-Her2 humanized monoclonal antibody data

GNE (South San Francisco) discussed with analysts the results of an open-label Phase II trial of its anti-Her2 MAb. Of 44 evaluable patients, 5 had a complete or partial response and 2 patients had minor responses. Three patients remain on maintenance therapy.

Patients received 250 mg intravenously over 90 minutes, followed by 100 mg iv weekly for 10 weeks. Patients who responded or had stable disease then received 100 mg iv weekly until their disease progressed. ...